Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Review

Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

Srijita Chatterjee S. Arya Nidhi Sharma M. Grover D. Yadav Hiba Parveen
Sep 2026 · Medical Oncology · Vol 43 · 0 citations · 62 references
Medicine

TL;DR

The rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit.

DOI PubMed Semantic Scholar
View source

Similar papers

Review Sep 2026

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer.

INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as 'undrugg...

Joanna Kreidi, C. Hoyek, C. Eslinger et al. · 0 citations
Review Sep 2026

Targeting KRAS-Mutant Lung Cancers.

KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.

E. Garbo, P. Scaparone, Hui Jing Hoe et al. · 0 citations
Review Sep 2026

Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V

The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.

T. Sagawa, Masahiro Hirakawa, H. Nagashima et al. · 1 citation
Review Open access Sep 2026

Current Landscape of RAS-Targeted Therapy for Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) continues to carry a poor prognosis, and only incremental gains in systemic therapy have been made over the past decade. Because activating KRAS mutations are present in more than 90% of PDAC and serve as the inciting oncogenic driver, RAS has long been a coveted but elusive ther...

Y. L. Wu, B. Herzberg, G. Manji · 0 citations
Review Aug 2026

Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.

This review summarizes recent progress in KRAS G12D-targeted inhibitors and degraders, highlighting current challenges and future opportunities for improving KRAS-directed cancer treatment.

Eun-Hyoung Jeon, Jaewon Song, Taebo Sim · 0 citations
Sep 2026

Abstract B074: Comparative analysis of next-generation KRAS inhibitors in patient derived pancreatic cancer organoids

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a five-year survival rate below 10%. Due to aggressiveness and lack of early detection methods, patients are often diagnosed at an advanced stage, leaving few therapeutic options. This emphasizes the need for a deeper understanding of the mo...

Paul G. Winckler, Georg Vladimirov, Lennart Herrlich et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.